Kawasaki Disease (KD) is a self-limiting systemic vasculitis common among children under five years of age. Diagnosis of the disease is made primarily from the clinical features presented during the illness. Coronary artery aneurysm (CAA) is the main complication of this disease which can be prevented largely by the early diagnosis and administration of IVIG (Intravenous Immunoglobulin). Even with first dose of IVIG up to 10% -20% of patients develop refractory Kawasaki Disease, i.e., remain unresponsive to initial IVIG treatment. Second dose of IVIG is recommended treatment for refractory Kawasaki Disease but other alternative treatments are also being considered to lower the risk of complications. Different drugs are still in trial phase and some others have limited studies on larger population. Most of the study reports that involved newer drugs have limited patients or are from single centers which are very hard to apply to larger population. We will review general treatment approach in refractory Kawasaki disease.
published in Japanese Journal of Allergy in the year 1967 with the title "Acute febrile mucocutaneous lymph node syndrome: clinical observation of 50 cases" [2] . This disease primarily affects medium sized arteries which complicate into acquired childhood cardiac disease. Kawasaki disease has replaced acute rheumatic fever as leading cause of childhood acquired cardiac disease in Japan, the United States and in Europe [3] .
Diagnosis
Diagnosis of Kawasaki is based on recognition of temporal features of clinical features presented during the illness. Diagnostic criteria [4] of Kawasaki consist of fever lasting for at least five days along with any four among these 5 clinical features, 1) Bilateral bulbar conjunctival injection; 2) Oral mucous membrane changes, including injected or fissured lips, injected pharynx, or strawberry tongue; 3) Peripheral extremity changes, including erythema of palms or soles, edema of hands or feet (acute phase), and periungual desquamation (convalescent phase); 4) Polymorphous rash; and 5) Cervical lymphadenopathy (at least 1 lymph node > 1.5 cm in diameter). Patient fulfilling these criteria are diagnosed with complete Kawasaki disease and those not fulfilling these criteria but having 2 or 3 criteria and a strong clinical suspicion of KD [5] can further be evaluated with the help of laboratory and echocardiographic evaluation and if further criteria fulfilled then those are diagnosed as incomplete Kawasaki disease.
Etiology
The etiology of KD remains unknown. Many theories have been proposed based on genetic, infectious and immune dysregulation. In Asian population several single nucleotide polymorphisms associated with susceptibility of KD, including FCGR2A, CASP3, HLA, BLK, ITPKC and CD40 [6] . In European population FCFR2A and ABCC4 have also been found to be susceptible to KD [7] [8] . Bacterial and viral infections like retrovirus, EPV, coronavirus, staphylococcal, streptococcal superantigens act like an infectious trigger of KD. These superantigens act by binding to Vβ regions of the T receptor and induce a widespread immunologic response resulting in release of TNF-α, IL-1β, IL-6 and IL-γ and these are felt to be directly related to fever, mucosal changes and desquamation in KD [9] . KD is classically considered to be due to immune dysregulation. It has been proposed that KD is similar to autoimmune disease in pathogenesis. T cells have been implicated in the inflammatory cascade in KD, with an emphasis on negative regulator of T cell activation. Loss of this regulator causes an increase in T cell activation and cytokine production and is hypothesized to have increased risk of coronary artery lesions [10].
Epidemiology
Incidence of Kawasaki disease is high in east Asian countries but reported all around the world. Fewer cases have been reported from Africa [11] and Latin [20] .
In western Australia a study [21] showed annual incidence of 2.82 per 100,000 children under five years in 1980-1989, 7.76 in 1990-1999 and 9.34 in 2000-2009. In New Zealand, a study [22] from January 2001 to December 2002 found annual incidence rate of 8/100,000 cases in children under five years.
Complications
The most serious complications of KD are cardiovascular complications. It may cause coronary artery aneurysm (CAA) and myocardial abnormalities. It affects medium size blood vessels, so coronary arteries are one of the most affected arteries. Dilatation of coronary arteries > 4 mm is considered dilation and when it is more than 8 mm it is called giant CA aneurysm. Other cardiac problems like decreased myocardial contractility, valvular regurgitation (mild) and pericardial effusion can also occur. CAA classification is done according to the Z-scoring system of the internal diameter of the lumen. CAA occurs in 25% -30% untreated patients [23] . Even with appropriate treatment there is up to 5% chances of CAA and CAA larger than 6 mm has strong relation with the myocardial ischemia [24] .
Initial Treatment
Recommended initial therapy for KD is Intravenous Immunoglobulin (IVIG) 2 g/kg and aspirin (Acetylsalicylic acid or ASA) 30 to 50 mg/kg/day (In Japan) -80 -100/mg/kg/day in four divided doses. IVIG is given over 8 -12 hours in a single infusion and has better outcome if given in 7 -10 days of illness. Same dose of IVIG and aspirin is given to complete and incomplete Kawasaki disease. This treatment is known to drop the occurrences of CAAs from 20% -25% to 3% -5% [25] .
Refractory Kawasaki Disease
Those patients who do not respond with initial treatment are considered to be a refractory KD. Initial IVIG resistant is seen in around 10% -20% of total KD patients whom IVIG is administered [5] . Patients having recrudescent fever or persistent fever 36 hours after the end of IVIG administration are considered to be 
Treatment after Resistant to Initial IVIG Treatment

Treatment Options after Failed Second IVIG Infusion
IVIG infusion more than 4 g/kg is not recommended in children due to risk of causing hemolytic anemia in children. Furthermore, other treatment options should be looked for ongoing vasculitis within the body to minimize the complications. Aspirin, IVIG and glucocorticoids are commonly used agents for KD but when there is failure with second dose of IVIG other drugs like tissue necrosis factor-alpha inhibitors, immunosuppressive agents and plasmapheresis can be considered. Figure 1 illustrates the available and optional treatment for Kawasaki Disease and IVIG resistant Kawasaki Disease. Though new drugs have shown safe and effective results in small studies but their therapeutic utility remains unproven [28] . Table 1 shows treatment options for Refractory Kawasaki
Disease that are currently available.
Glucocorticoid Therapy
Glucocorticoid therapy can be given along with first IVIG infusion in a high risk patient. Furthermore, it can also be given after initial IVIG resistant as an alternative days. In a study [29] conducted in Japan on 63 patients who didn't respond to initial IVIG treatment, 44 patients those not responding with first dose of IVIG were treated with methylprednisolone (30 mg/kg per day for 3 days) and 19 remaining treated with second dose of IVIG. Among 44 patients those treated with methylprednisolone 34 had resolutions of fever. In other group with second dose of IVIG group 12 patients out of 19 patients had resolution of fever. All patients who had not responded with methylprednisolone or second IVIG infusion were again given another course of methylprednisolone. All together 8 patients had
CAAs. 5 out of 10 who failed to respond to methylprednisolone and 2 out of 7 who failed to respond to second dose of IVIG developed CAAs.
Tumor Necrosis Factor (TNF)-Alpha Inhibition
Elevations of tissue necrosis factors are characteristic feature of KD, so anti-TNF-α agents such as infliximab and etanercept have been studied in the treatment of KD. These agents can rapidly normalize laboratory markers of Showed improvement in reduction of symptoms but no in improvement or prevention of CAL [39] inflammation in IVIG-resistant cases of KD. In a randomized multicenter trial [30] , initial IVIG resistant were given infliximab (5 mg/kg IV) or second dose of IVIG. Fever resolved in 11 out of 12 patients with infliximab group and 8 out of 12 patients another group who were given second dose of IVIG. Progression of CAAs was similar in both groups. Etanercept is another anti-TNF-α agent which is under the study for the treatment of primary KD. Not many reports have been 
Interleukin-1 (IL-1) Inhibition
IL-1 elevation has been reported in Kawasaki disease that may be linked to co- numab are in trial for treating refractory KD. Initial reports suggesting these drugs are safe to children but data regarding their efficacy is still not available [32] . In a study conducted by Dusser P et al. [33] IL-1 blockade treatment such as anakinra showed successful improvement in myocarditis and aneurysm that was formed in a mouse model of KD.
Plasmapheresis
Plasmapheresis is effective in acute inflammatory conditions. Kawasaki disease is an acute inflammatory disease so plasmapheresis is ideal condition for this intervention. Kawasaki itself is self-limiting disease and plasmaphereses being very complex and hazardous conditions [34] , it is suggested to use it in those children who have undergone all the other pharmacologic treatment and still having active vasculitis. In a study [35] 
Summary and Prospective
Since first coining the name good outcomes on responding fever but have not shown more beneficial effects on CAAs. These drugs can also be used after the failure of second IVIG infusion.
Furthermore, immunosuppressive, plasmapheresis are also alternatives but due to their limited studies and more toxicity and hazardous procedures, they should be limited to those refractory cases that were first treated with recommended pharmacologic agents.
